SBR759

DRUG3 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Chronic Kidney DiseaseHyperphosphatemia Patients With Chronic Kidney Disease on 3x/Week Replacement Therapy

Phase 1

A Clinical Study to Evaluate the Safety, Tolerability and Activity of a New Phosphate Binder (SBR759) in Patients With Chronic Kidney Disease on Hemodialysis

CompletedNCT00750295

Novartis PharmaceuticalsChronic Kidney Disease

Start: 2007-02-28End: 2008-01-31Updated: 2020-12-19

Phase 2

Efficacy of SBR759 in Lowering Serum Phosphate Levels in Chronic Kidney Disease Patients on Hemodialysis

CompletedNCT00704483

Novartis PharmaceuticalsHyperphosphatemia Patients With Chronic Kidney Disease on 3x/Week Replacement Therapy

Start: 2008-07-31Updated: 2020-12-19

Optimal Titration Regimen for SBR759 in Lowering Serum Phosphate Levels in Asian Chronic Kidney Disease Patients on Hemodialysis

CompletedNCT00704678

Novartis PharmaceuticalsChronic Kidney Disease

Start: 2008-08-31Updated: 2016-09-23